World Health Organization Sounds Warning Over Acute Lack of Weight-Loss Jabs

Less than 10% of individuals who could benefit from weight-loss injections including Wegovy can access them, caution the World Health Organization as it releases its first advice on the therapies.

With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication.

According to forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"Our new guidelines recognises that obesity is a long-term condition that can be addressed with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are key obstacles to broad access to the jabs that can aid individuals in losing significant weight, explains the body.

GLP-1 Therapy Scarcity

Even in the current most optimistic scenario, the supply of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.

The guideline encourages governments and firms to expand access, via strategies including licensing agreements.

A patent on a key compound – the core ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.

How Obesity Jabs Work

These medications imitate a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people eat less.

Individuals usually see weight reduction within a few weeks of beginning the weekly injections.

Studies points to patients may regain a significant portion within a year of halting the treatment, because their normal appetite return.

Being above a healthy weight increases your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.